203 related articles for article (PubMed ID: 9781932)
21. Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure.
Baumann G; Ningel K; Permanetter B
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S23-30. PubMed ID: 2478788
[TBL] [Abstract][Full Text] [Related]
22. Comparison of intravenous amrinone and dobutamine in congestive heart failure due to idiopathic dilated cardiomyopathy.
Marcus RH; Raw K; Patel J; Mitha A; Sareli P
Am J Cardiol; 1990 Nov; 66(15):1107-12. PubMed ID: 2220638
[TBL] [Abstract][Full Text] [Related]
23. Piroximone, dobutamine and nitroprusside: comparative effects on haemodynamics in patients with congestive heart failure.
Baumann G; Ningel K; Vieweg J; Joder-Ohlenbusch AM; Cremer G
Eur Heart J; 1991 Apr; 12(4):533-40. PubMed ID: 2065688
[TBL] [Abstract][Full Text] [Related]
24. [Additive effects of milrinone and dobutamine in severe heart failure].
Meissner A; Herrmann G; Gerdesmeyer L; Simon R
Z Kardiol; 1992 May; 81(5):266-71. PubMed ID: 1621407
[TBL] [Abstract][Full Text] [Related]
25. Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure.
Mikulic E; Cohn JN; Franciosa JA
Circulation; 1977 Oct; 56(4 Pt 1):528-33. PubMed ID: 902377
[TBL] [Abstract][Full Text] [Related]
26. A randomized comparison of intravenous amrinone versus dobutamine in older patients with decompensated congestive heart failure.
Rich MW; Woods WL; Davila-Roman VG; Morello PJ; Kurz H; Barbarash R; Spinner L; Sperry J; Beckham V; Coulter L
J Am Geriatr Soc; 1995 Mar; 43(3):271-4. PubMed ID: 7884117
[TBL] [Abstract][Full Text] [Related]
27. Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure.
Grose R; Strain J; Greenberg M; LeJemtel TH
J Am Coll Cardiol; 1986 May; 7(5):1107-13. PubMed ID: 3958369
[TBL] [Abstract][Full Text] [Related]
28. Dobutamine in severe scorpion envenomation: effects on standard hemodynamics, right ventricular performance, and tissue oxygenation.
Elatrous S; Nouira S; Besbes-Ouanes L; Boussarsar M; Boukef R; Marghli S; Abroug F
Chest; 1999 Sep; 116(3):748-53. PubMed ID: 10492282
[TBL] [Abstract][Full Text] [Related]
29. Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure.
Wimmer A; Stanek B; Kubecova L; Vitovec J; Spinar J; Yilmaz N; Kos T; Hartter E; Frey B; Pacher R
Jpn Heart J; 1999 May; 40(3):321-34. PubMed ID: 10506854
[TBL] [Abstract][Full Text] [Related]
30. Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Eichhorn EJ; Konstam MA; Weiland DS; Roberts DJ; Martin TT; Stransky NB; Salem DN
Am J Cardiol; 1987 Dec; 60(16):1329-33. PubMed ID: 3687783
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of dobutamine and a phosphodiesterase inhibitor on early diastolic filling in patients with congestive heart failure.
Nagata K; Iwase M; Sobue T; Yokota M
J Am Coll Cardiol; 1995 Feb; 25(2):295-304. PubMed ID: 7829780
[TBL] [Abstract][Full Text] [Related]
32. Automated drug delivery system to control systemic arterial pressure, cardiac output, and left heart filling pressure in acute decompensated heart failure.
Uemura K; Kamiya A; Hidaka I; Kawada T; Shimizu S; Shishido T; Yoshizawa M; Sugimachi M; Sunagawa K
J Appl Physiol (1985); 2006 Apr; 100(4):1278-86. PubMed ID: 16373447
[TBL] [Abstract][Full Text] [Related]
33. [The hemodynamic profile of amrinone and enoximone in patients with severe heart failure].
Saborowski F; Peters P; Schneider M
Z Kardiol; 1991; 80 Suppl 4():63-7. PubMed ID: 1833900
[TBL] [Abstract][Full Text] [Related]
34. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy.
Biddle TL; Benotti JR; Creager MA; Faxon DP; Firth BG; Fitzpatrick PG; Konstam MA; Krebs C; Walton L; Kershner RP
Am J Cardiol; 1987 Jun; 59(15):1345-50. PubMed ID: 3591689
[TBL] [Abstract][Full Text] [Related]
35. Relative contribution of inotropic and vasodilator effects to amrinone-induced hemodynamic improvement in congestive heart failure.
Konstam MA; Cohen SR; Weiland DS; Martin TT; Das D; Isner JM; Salem DN
Am J Cardiol; 1986 Feb; 57(4):242-8. PubMed ID: 3004184
[TBL] [Abstract][Full Text] [Related]
36. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Metra M; Nodari S; D'Aloia A; Muneretto C; Robertson AD; Bristow MR; Dei Cas L
J Am Coll Cardiol; 2002 Oct; 40(7):1248-58. PubMed ID: 12383572
[TBL] [Abstract][Full Text] [Related]
37. [Enoximone, vasodilator and/or inotropic agent in congestive cardiac insufficiency? Hemodynamic and ventriculographic study of 20 cases].
Durrieu C; Rochoux G; Coste P; Le Goff G; Besse P
Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():43-50. PubMed ID: 2147834
[TBL] [Abstract][Full Text] [Related]
38. [Acute changes in the hemodynamic profile and circulating levels of atrial natriuretic peptide induced by dobutamine in severe heart failure].
La Vecchia L; Bottero M; Centofante P; Bedogni F; Ometto R; Cera A; Fortunato A
G Ital Cardiol; 1996 Aug; 26(8):863-74. PubMed ID: 9005168
[TBL] [Abstract][Full Text] [Related]
39. Milrinone. A preliminary review of its pharmacological properties and therapeutic use.
Young RA; Ward A
Drugs; 1988 Aug; 36(2):158-92. PubMed ID: 3053125
[TBL] [Abstract][Full Text] [Related]
40. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure.
Maskin CS; Sinoway L; Chadwick B; Sonnenblick EH; Le Jemtel TH
Circulation; 1983 May; 67(5):1065-70. PubMed ID: 6831672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
